Welcome to visit Zhongnan Medical Journal Press Series journal website!
Zhongnan Medical Journal Press Series of Journals Center for Evidence-Based and Translational Medicine of Wuhan University

The title
  • The title
  • The keywords
  • The author
Submit中文版

HomeArticlesVol 30,2020 No.4Detail

Analysis of the burden of prostate cancer in China in 1990 and 2017

Published on Aug. 21, 2020Total Views: 7251 timesTotal Downloads: 2935 timesDownloadMobile

Author: Tong DENG 1, 2 Lin CAI 3, 4 Zheng CHEN 5 Jia GUO 6 Xing HUANG 1, 7, 8, 9 Chang-Xing KE 10 Wen-Zhi LI 11 Li JIANG 12, 13, 14 Guan-Jun LU 15 Xiao-Qiang LIU 16 Jin-Hai FAN 17, 18* Xian-Tao ZENG 1, 7*

Affiliation: 1. Center for Evidence-Based and Translational Medicine, Zhongnan Hospital of Wuhan University, Wuhan 430071, China 2. Institutes of Evidence-Based Medicine and Knowledge Translation, Henan University, Kaifeng 475000, Henan Province, China 3. Department of Urology, Peking University First Hospital, Beijing 100034, China 4. Institute of Urology, Peking University, Beijing 100034, China 5. Department of Urologic Sciences, University of British Columbia, British Columbia V5Z 1M9, Canada 6. Department of Urology, People's Hospital of Wuhan University, Wuhan 430060, China 7. Department of Urology, Zhongnan Hospital of Wuhan University, Wuhan 430071, China 8. Institute of Urology, Wuhan University, Wuhan 430071, China 9. Hubei Provincial Engineering Research Center for Precision Diagnosis and Therapy Technology and Translational Medicine, Wuhan 430071, China 10. Department of Urology, Second Affiliated Hospital of Kunming Medical University, Kunming 650000, China 11. Department of Urology, Ninth People's Hospital, Shanghai Jiaotong University School of Medicine, Shanghai 200011, China 12. National Cancer Center, Beijing 100021, China 13. National Cancer Clinical Medical Research Center, Beijing 100021, China 14. Cancer Early Diagnosis and Early Treatment Office, Cancer Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing 100021, China 15. Department of Urology, The General Hospital of Ningxia Medical University, Yinchuan 750004, China 16. Department of Urology, the First Affiliated Hospital of Nanchang University, Nanchang 330000, China 17. Department of Urology, First Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710000, China 18. Institute of Urology, Xi'an Jiaotong University, Xi'an 710000, China

Keywords: Prostate cancer Incidence Mortality Burden of disease Disability-adjusted life years

DOI: 10.12173/j.issn.1004-5511.2020.04.01

Reference: Deng T, Cai L, Chen Z, Guo J, Huang X, Ke CX, Li WZ, Jiang L, Lu GJ, Liu XQ, Fan JH, Zeng XT. Analysis of the burden of prostate cancer in China in 1990 and 2017[J]. Yixue Xinzhi Zazhi, 2020, 30(4): 252-259. DOI: 10.12173/j.issn.1004-5511.2020.04.01.[Article in Chinese]

  • Abstract
  • Full-text
  • References
Abstract

Objective  To analyze the trend of incidence, mortality and disease burden of prostate cancer in China between 1990 and 2017. 

Methods  Based on the results of the Global Burden of Diseases 2017 (GBD 2017), Incidence, Mortality, Disability-Adjusted Life Years (DALY), Years of Life Lost (YLL), and Years Lived with Disability (YLD) of prostate cancer and its standardized rate were used to describe the burden of prostate cancer in China between 1990 and 2017.

Results  In 2017, the number of cases of prostate cancer in China was 144,900, the standardized incidence was 16.57 / 100 000, the number of deaths was 51,700, and the standardized mortality was 6.8 / 100 000. Compared with 1990, the number of cases increased by 432.72%, the standardized incidence increased by 98.21%, the number of deaths increased by 158.5%, and the standardized mortality decreased by 3.82%. Incidence and mortality are increasing with age. Compared with 1990, in 2017, the DALY standardization rate of prostate cancer in China decreased by 3.81%, the YLL standardization rate decreased by 9.73%, and the YLD standardization rate increased by 134.56%. 

Conclusions  Compared with 1990, the overall disease burden of prostate cancer in China in 2017 showed a downward trend, but YLD showed an upward trend. The burden of prostate cancer disease in the elderly is still high and should be the focus of attention.

Full-text
Please download the PDF version to read the full text: download
References

1.  Braunhut BL, Punnen S, Kryvenko ON. Updates on Grading and Staging of Prostate Cancer[J]. Surg Pathol Clin, 2018, 11(4): 759-774. DOI: 10.1016/j.path.2018.07.003.

2.  Global Burden of Disease Cancer Collaboration, Fitzmaurice C, Abate D, et al. Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-Years for 29 Cancer Groups, 1990 to 2017: A Systematic Analysis for the Global Burden of Disease Study [J]. JAMA Oncol, 2019, 5(12): 1749-1768. DOI: 10.1001/jamaoncol.2019.2996.

3.  Miller KD, Siegel RL, Lin CC, et al. Cancer treatment and survivorship statistics, 2016[J]. CA Cancer J Clin, 2016, 66(4): 271-289. DOI: 10.3322/caac.21349.

4.  毕新刚, 韩仁强, 周金意,等. 2009年中国前列腺癌发病和死亡分析[J]. 中国肿瘤, 2013, 22(6): 417-422. DOI:  10.11735/j.issn.1004-0242.2013.06.A201304125. [Bi XG, Han RQ, Zhou JY, et al. Analysis of Incidence and Death of Prostate Cancer in China in 2009[J]. China Cancer, 2013, 22 (6): 417-422.]

5.  James SL, Abate D, Abate KH, et al. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017[J]. The Lancet, 2018, 392(10159): 1789-1858. DOI: 10.1016/S0140-6736(18)32279-7.

6.  Kyu HH, Abate D, Abate KH, et al. Global, regional, and national disability-adjusted life-years (DALYs) for 359 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017[J]. The Lancet, 2018, 392(10159): 1859-1922. DOI: 10.1016/S0140-6736(18)32335-3.

7.  Roth GA, Abate D, Abate KH, et al. Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980–2017: a systematic analysis for the Global Burden of Disease Study 2017[J]. The Lancet, 2018, 392(10159): 1736-1788. DOI: 10.1016/S0140-6736(18)32203-7.

8.  Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012[J]. Int J Cancer, 2015, 136(5): E359-E386. DOI: 10.1002/ijc.29210.

9.  韩苏军, 张思维, 陈万青, 等. 中国前列腺癌发病现状和流行趋势分析[J]. 临床肿瘤学杂志, 2013, 18(4): 330-334. DOI: 10.3969/j.issn.1009-0460.2013.04.009. [Han SJ, Zhang SW, Chen WQ, et al. Analysis of the status and trends of prostate cancer incidence in China[J]. Chinese Clinical Oncology, 2013, 18(4): 330-334.]

10. 韩苏军, 张思维, 陈万青,等. 中国前列腺癌死亡现状及流行趋势分析[J]. 中华泌尿外科杂志, 2012, 33(11): 836-839. DOI: 10.3760/cma.j.issn.1000-6702.2012.11.010. [Han SJ, Zhang SW, Chen WQ, et al. Analysis of the status and trends of prostate cancer mortality in China[J]. Chinese Journal of Urology, 2012, 33(11): 836-839.]

11. Rebbeck TR, Devesa SS, Chang BL, et al. Global patterns of prostate cancer incidence, aggressiveness, and mortality in men of african descent[J]. Prostate Cancer, 2013, 2013: 560857. DOI: 10.1155/2013/560857.

12. Center MM, Jemal A, Lortet‐Tieulent J, et al. International variation in prostate cancer incidence and mortality rates[J]. Eur Urol, 2012, 61: 1079-1092. DOI: 10.1016/j.eururo.2012.02.054.

13. Chen W, Zheng R, Zhang S, et al. Cancer incidence and mortality in China, 2013[J]. Cancer Lett, 2017, 401: 63-71. DOI: 10.1016/j.canlet.2017.04.024.

14. Feletto E, Bang A, Cole-Clark D, et al. An examination of prostate cancer trends in Australia, England, Canada and USA: Is the Australian death rate too high? [J]. World J Urol, 2015, 33(11): 1677-1687. DOI: 10.1007/s00345-015-1514-7.

Popular Papers
© 2022 - 2024 Zhongnan Medical Journal Press of Zhongnan Hospital of Wuhan University|Support: Yufu Technology
About NM | Contact us